Advanced oxidative protein products are independently associated with endothelial function in peritoneal dialysis patients

Nephrology

Volumn 14, Issue 3, 2009, Pages 273-280

  Kocak, Huseyin ^a   Gumuslu, Saadet ^a   Sahin, Emel ^a   Ceken, Kaan ^a   Gocmen, Yesim A ^a   Yakupoglu, Gulsen ^a   Ersoy, F Fevzi ^a   Tuncer, Murat ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Advanced oxidation protein products; Asymmetric dimethylarginine; Endothelial function; Peritoneal dialysis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; MALONALDEHYDE; N(G),N(G) DIMETHYLARGININE; PENTOSIDINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

ADULT; ARGININE; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; PERITONEAL DIALYSIS; REGRESSION ANALYSIS;

EID: 65349134753     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.01062.x     Document Type: Article

References (40)

1. Locatelli F, Marcelli D, Conte F et al. Cardiovascular disease in chronic renal failure: The challenge continues. Registro Lombardo Dialisi e Trapianto. Nephrol. Dial. Transplant. 2000 15 : 69 80.
2. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J. Am. Soc. Nephrol. 1997 8 : 475 86.
3. Menon V, Gul A, Sarnak MJ. Cardiovascular risk factors in chronic kidney disease. Kidney Int. 2005 68 : 1413 18.
4. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int. 2003 63 : 105 10.
5. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr. Opin. Nephrol. Hypertens. 2004 13 : 93 9.
6. Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr. Opin. Nephrol. Hypertens. 2003 12 : 593 8.
7. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996 49 : 1304 13.
8. Anderson TJ. Assessment and treatment of endothelial dysfunction. J. Am. Coll. Cardiol. 1999 34 : 631 8.
9. van Guldener C, Lambert J, Janssen MJ, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol. Dial. Transplant. 1997 12 : 14 18.
10. Morris ST, McMurray JJ, Rodger RS, Jardine AG. Impaired endothelium-dependent vasodilatation in uraemia. Nephrol. Dial. Transplant. 2000 15 : 1194 200.
11. van Guldener C, Janssen MJ, Lambert J, Steyn M, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation is impaired in peritoneal dialysis patients. Nephrol. Dial. Transplant. 1998 13 : 1782 86, 1998.
12. Kocak H, Ceken K, Yavuz A et al. Effect of renal transplantation on endothelial function in hemodialyis patients. Nephrol. Dial. Transplant. 2006 21 : 2003 7.
13. Yilmaz MI, Saglam M, Caglar K et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. Transplantation 2005 12 : 1660 6.
14. Simmons EM, Langone A, Sezer MT et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end stage renal disease patients. Transplantation 2005 79 : 914 9.
15. Sydow K, Münzel T. ADMA and oxidative stress. Atherosclerosis 2003 Suppl 4 41 51.
16. Sahn DJ, Demaria A, Kisslo J, Weyman A,. Recommendations regarding quantitation in M-mode echocardiography. Results of a survey of echocardiographic measurements. Circulation 1978 58 : 1072 83.
17. Devereux B, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am. J. Cardiol. 1986 57 : 450 8.
18. Savage DD, Garrison RJ, Kannel WB et al. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham Study. Circulation 1987 75 (Suppl I I-26 I-33.
19. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003 289 : 2560 72.
20. Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992 340 : 1111 6.
21. Henle T, Deppisch R, Beck W, Hergesell O, Hansch GM, Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol. Dial. Transplant. 1999 14 : 1968 75, 1999.
22. Kalousova M, Zima T, Tesar V, Lachmanova J. Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients. Blood Purif. 2002 20 : 531 6.
23. Gugliucci A, Menini T. Circulating advanced glycation peptides in streptozotocin-induced diabetic rats: Evidence for preferential modification of IgG light chains. Life Sci. 1998 62 : 2141 50.
24. Wasowicz W, Neve J, Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum: Importance of extraction pH and influence of sample preservation and storage. Clin. Chem. 1993 39 : 2522 6.
25. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951 193 : 265 75.
26. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004 109 : 27 32.
27. Adams MR, Robinson J, McCredie R et al. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J. Am. Coll. Cardiol. 1998 32 : 123 27.
28. Taylor JE, Scott N, Bridges A, Henderson IS, Stewart WK, Belch JJ. Lipid peroxidation and antioxidants in continuous ambulatory dialysis patients. Perit. Dial. Int. 1992 12 : 252 6.
29. Canestrari F, Buoncristiani U, Galli F et al. Redox state, antioxidative activity and lipid peroxidation in erythrocytes and plasma of chronic ambulatory peritoneal dialysis patients. Clin. Chim. Acta 1995 234 : 127 36.
30. Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: A nephrologist's perspective. Am. J. Kidney Dis. 2000 35 : 365 80, 2000.
31. Ateshkadi A, Johnson CA, Founds HW, Zimmerman SW. Serum advanced glycosylation end-products in patients on hemodialysis and CAPD. Perit. Dial. Int. 1995 15 : 129 33.
32. Joannides R, Haefeli WE, Linder L et al. Nitric oxide is responsible forflow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995 91 : 1314 9.
33. Mittermayer F, Schaller G, Pleiner J et al. Asymmetrical dimethylarginine plasma concentrations are related to basal nitric oxide release but not endothelium-dependent vasodilation of resistance arteries in peritoneal dialysis patients. J. Am. Soc. Nephrol. 2005 16 : 1832 8.
34. Hamilton CA, Miller WH, Al-Benna S et al. Strategies to reduce oxidative stress in cardiovascular disease. Clin Sci. (Lond) 2004 106 : 219 34.
35. Furuya R, Odamaki M, Kumagai H, Hishida A. Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients. Blood Purif. 2006 24 : 445 50.
36. Horl WH, Cohen JJ, Harrington JT, Madias NE, Zusman CJ. Atherosclerosis and uremic retention solutes. Kidney Int. 2004 66 : 1719 31, 2004.
37. Descamps-Latscha B, Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure. Kidney Int. 2001 78 : 108 13.
38. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002 162 : 221 5.
39. Drueke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002 106 : 2212 7.
40. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am. J. Kidney Dis. 2005 45 : 39 47.